- The development of HEC-866 and its analogues for the treatment of idiopathic pulmonary fibrosis
-
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a typical survival time between three to five years. Two drugs, pirfenidone and nintedanib have been approved for the treatment of IPF, but they have limited efficacy. Thus, th
- Cao, Shengtian,Li, Jing,Lin, Runfeng,Wang, Xiaojun,Xu, Juan,Yang, Wen,Yang, Xinye,Zhang, Jiancun,Zhang, Zheng,Zuo, Yinglin
-
supporting information
p. 1222 - 1231
(2021/11/02)
-
- COMPOUNDS AND USES THEREOF
-
The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.
- -
-
Page/Page column 70
(2020/08/13)
-
- SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS
-
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, n, W, X, Y, Z, R1, R22, R3, R4 and R5 are as defined in the specificatio
- -
-
-
- NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS
-
The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, IPF, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.
- -
-
Paragraph 00269; 00274
(2015/07/07)
-
- 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS
-
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R1 , R2, R3, R4 and R5 are as defined in the specification, composition
- -
-
-
- SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES
-
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof : (I) in which m, n, W, X, Y, Z, R1, R2, R3 and R4 are as defined in the specification, for use in the treatm
- -
-
-
- THERAPEUTIC COMPOUNDS
-
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R, R1, R2, R3 and R4 are as defined in the specification, for use in therapy.
- -
-
Paragraph 0647; 0648; 0649
(2014/01/07)
-
- The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists
-
Bipiperidine amide 1 has been identified as a CC chemokine receptor 3 (CCR3) antagonist. Optimization of its structure-activity relationship has resulted in the identification of cis (R,R)-4-[(3,4-dichlorophenyl)methyl]-3- hydroxymethyl-1′(6-quinolinylcar
- Ting, Pauline C.,Lee, Joe F.,Wu, Jie,Umland, Shelby P.,Aslanian, Robert,Cao, Jianhua,Dong, Youhao,Garlisi, Charles G.,Gilbert, Eric J.,Huang, Ying,Jakway, James,Kelly, Joseph,Liu, Zhidan,McCombie, Stuart,Shah, Himanshu,Tian, Fang,Wan, Yuntao,Shih, Neng-Yang
-
p. 1375 - 1378
(2007/10/03)
-